Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Yatharth Hospital & Trauma Care Services Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
5 Aug 2026
Yatharth Hospital & Trauma Care Services Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
The company has maintained a strong growth trajectory, with a consistent ~30% year-on-year revenue growth over the past few years. Key concall takeaways from…
5 Aug 2026
Oriana Power Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
EPS shows significant growth: H1 FY26 EPS at ₹59.77 per share, up from ₹24.84 previously. Key concall takeaways from Oriana Power Ltd's Q2 FY26 earnings call…
5 Aug 2026
Infollion Research Services Q4 FY26 earnings call: Revenue & Margins | Arthneeti
Q4 FY26
10 crores this year, enhancing capacity to accelerate investments when relevant opportunities arise. Key concall takeaways from Infollion Research Services…
5 Aug 2026
Netweb Technologies India Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
3,000 crores. Key concall takeaways from Netweb Technologies India Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
Netweb Technologies India Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
The current order pipeline stands at approximately INR 4,000 crores. Key concall takeaways from Netweb Technologies India Ltd's Q4 FY25 earnings call — and how…
5 Aug 2026
Senco Gold Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Volume growth for Q3 FY26: Gold volume declined by 3% quarter-on-quarter; 9-month gold volume down 10%, while diamond volume up 12.5% (grammage basis). Key…
5 Aug 2026
Senco Gold Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Highest-ever sales recorded in October at INR 1,700 crores, up from INR 1,100 crores last year. Key concall takeaways from Senco Gold Ltd's Q2 FY26 earnings…
5 Aug 2026
Senco Gold Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Gold volume saw a decline of 6% in Q4 FY25 and approximately 3% for the full year FY25 due to price increases. Key concall takeaways from Senco Gold Ltd's Q4…
5 Aug 2026
Cyient DLM Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Current order book stands at approximately INR 2,300 crores. Key concall takeaways from Cyient DLM Ltd's Q2 FY26 earnings call — and how it ranks against…
5 Aug 2026
Cyient DLM Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Current capacity utilization at 55-60%; potential to nearly double revenue by running 3 shifts without major new CAPEX. Key concall takeaways from Cyient DLM…
5 Aug 2026
Cyient DLM Q3 FY25: Order Book ₹2,142.9 Cr | Arthneeti
Q3 FY25
Consolidated order backlog stands at ₹2,142.9 crore, including ₹291.5 crore from Altek. Key concall takeaways from Cyient DLM Ltd's Q3 FY25 earnings call — and…
5 Aug 2026
Kaka Industries Q4 FY25: Revenue ₹400 Cr | Arthneeti
Q4 FY25
Confident in achieving 40% volume growth due to increased production capacity and expanded sales force. Key concall takeaways from Kaka Industries Ltd's Q4…
5 Aug 2026
Nexus Select Trust Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Nine months NOI growth stood at 6% with rental escalations contributing 4%-4.5%, re-leasing spreads adding 1%-1.5%, and flat revenue share (Rajesh Deo, p14)…
5 Aug 2026
Mankind Pharma Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Domestic BSV growth is driven by both Rx and specialty segments (e.g., fertility drugs with 10-35%+ growth, anti-snake venom with high double-digit growth)…
5 Aug 2026
Mankind Pharma Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Overall revenue growth in FY '25 was 19% year-on-year, with optimism for continued strong performance ahead. Key concall takeaways from Mankind Pharma Ltd's Q4…
5 Aug 2026
Mankind Pharma Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Chronic segment is growing faster and gaining share, currently at 37.6% of sales, up 200 bps YoY. Key concall takeaways from Mankind Pharma Ltd's Q3 FY25…
5 Aug 2026
Avalon Technologies Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Order book stood at INR1,790 crores with a 22.5% year-on-year increase, plus INR1,157 crores from long-term contracts (15-36 months), indicating sustained…
5 Aug 2026
Cube Highways Trust Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Strong traffic growth of 9.4% YoY observed recently, supported by sustained increase in passenger car traffic due to rising vehicle sales and disposable…
5 Aug 2026
De Neers Tools Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Expansion plans include adding 25%-35% more distributors and focusing on deepening penetration into Tier 2 and Tier 3 cities (Page 9, 15). Key concall…
5 Aug 2026